J. C. BHALLA & CO.
CHARTERED ACCOUNTANTS

HEAD OFFICE: B-17, Maharani Bagh, New Delhi-110065
Tel.: +91-11-41552255
E-MAIL: taxaid@jcbhalla.com

CERTIFICATE ON TRANSLATED VERSION OF MATERIAL SUBSIDIARY AUDITED FINANCIAL STATEMENTS

To,
The Board of Directors
Integris Medtech Limited ***(formerly known as Integris Medtech Private Limited and Integris Health Private Limited)***
1st Floor, Metro Tower LSC,
M.O.R Land, New Rajinder Nagar,
New Delhi -110060, India.

LAMED Vertriebsgesellschaft
Gleißental Str. 5a, 82041 Oberhaching

Dear Ladies and Gentlemen,

Re: Proposed initial public offering of equity shares (the "Equity Shares") of Integris Medtech Limited (the "Company", and such initial public offering, the "Offer")

This certificate is issued in accordance with the terms of our engagement letter with the Company dated October 07, 2025.

We have verified the translated version of the audited standalone financial statements (the "Annexure") of **LAMED Vertriebsgesellschaft.** (the "Subsidiary Company") for the periods ended March 31, 2025 and March 31, 2024 ("Financial Years"). These financial statements have been translated by the Company in Indian Rupee in accordance with Ind AS 21, 'The Effect of Changes in Foreign Currency Rates'. The work carried out by us is in accordance with the Standard on Related Services (SRS) 4400, "Engagements to Perform Agreed-upon Procedures regarding Financial Information" issued by the Institute of Chartered Accountants of India.

As required under Schedule VI Part A item no.(11)(I)(A)(ii)(b) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), the Company has prepared the translated version of the audited standalone financial statements contained in the Annexure attached to this certificate which is proposed to be uploaded on the website of the Company in connection with the Offer.

The preparation of the accompanying translated version of the audited standalone financial statements for the Financial Years is the responsibility of the management of the Company including the preparation and maintenance of all accounting and other relevant supporting records and documents. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the Annexure and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

The management of the Company is also responsible for ensuring that the Annexure complies with all the relevant requirements of the SEBI Regulations inter alia Schedule VI Part A item no.(11)(I)(A)(ii)(b) of Securities and Exchange Board of India (Issue of Capital and Disclosure

Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and requirement of IND AS 21.

Our Responsibility is to Examine that the financial statements have been translated by the Company in Indian Rupee in accordance with Ind AS 21, 'The Effect of Changes in Foreign Currency Rates'.

Accordingly, we have performed the following procedures in relation to the Annexure:

a. Obtained the Copy of Audited Financial Statements for the Financial Periods of the Subsidiary Company and auditors report thereon.
b. Compared the content of the Annexure from the Audited Financial Statements of the Subsidiary Company.
c. Verified the arithmetical accuracy of the information included in the Annexure.
d. Ensure that the translation has done in accordance with the IND AS 21.
e. Made necessary inquiries with the management of the Company and obtained relevant representations in respect of matters relating to the Annexure.

Based on our examination, we confirm that the information in this Annexure is true, fair, correct, accurate and there is no untrue statement or omission which would render the contents of this certificate misleading in its form or context.

We did not audit the standalone financial statements of **LAMED Vertriebsgesellschaft**. These financial statements have been audited by other audit firms, whose reports have been furnished to us by the Company.

These translated financials should not in any way be construed as a reissuance or re-dating of any of the previous audit reports, nor should these be construed as a new opinion on any of the audited standalone financial statements referred to herein.

These translated financials are intended solely for use of the management for uploading on website of **the Company** in connection with the Offer.

This certificate has been provided by us at the request of the Company and solely for the information of **Axis Capital Limited, Citigroup Global Markets India Private Limited, ICICI Securities Limited, IIFL Capital Services Limited,** (collectively referred to as the "Book Running Lead Managers" or the "**BRLMs**") and **Board of Directors of the Company** to assist them in conducting their due-diligence and documenting their investigations of the affairs of the Company in connection with the proposed Offer. This certificate may be relied on by the BRLMs, their affiliates and legal counsel in relation to the Offer.

This certificate is not intended for general circulation or publication and is not to be reproduced or used for any other purpose without our prior consent in writing, other than for the purpose stated above. We, however, hereby give consent for inclusion of our name and this information (in full or in part) in the Draft Red Herring Prospectus, Red Herring Prospectus and Prospectus proposed to be filed by the Company with the Securities and Exchange Board of India ("**SEBI**"), the stock exchanges where the Equity Shares of the Company are proposed to be listed (the "**Stock Exchanges**") with the Registrar of Companies ("**ROC**") and any other material used in connection with the Offer and submission of this certificate to SEBI, Stock Exchanges, or ROC in connection with the proposed Offer, as the case may be. Additionally, we hereby give our consent for the submission of this certificate to any

J C BHALLA & CO. Chartered Accountants

other regulatory authority as may be required under applicable law in connection with the proposed Offer, as the case may be.

Yours Sincerely,

For J C Bhalla & Co.
Chartered Accountants
Firm Regn No. 001111N



(Akhil Bhalla)
Partner
Membership No. 505002
UDIN: 25505002BMIMMN5181

Place: New Delhi
Date:

cc:
Legal Counsel to the Lead Managers as to Indian Law

S&R Associates
One World Centre, 1403 Tower 2 B
841 Senapati Bapat Marg
Lower Parel, Mumbai 400 013
Maharashtra, India

Legal Counsel to the Lead Managers as to U.S. Law

Linklaters Singapore Pte Ltd.

#28-01, West Tower

IOI Central Boulevard Towers

Singapore 018 916

Legal Counsel to the Company as to Indian Law

Cyril Amarchand Mangaldas
Level 1 and Level 2, Max Towers
Plot No. C-001/ A/1, Sector 16 B
Gautam Buddha Nagar
Noida 201 301
Uttar Pradesh, India

LAMED Vertriebsgesellschaft
Translated Version of Statement of Financial Position for the Financial year ended 31 March 2025
(All amounts in EURO/INR lakhs, unless stated otherwise)

Particulars	Notes	EURO As at 31 March 2025	EURO As at 31 March 2024	INR As at 31 March 2025	INR As at 31 March 2024
Assets					
Non-current assets					
Property, plant and equipments	4	1.62	1.14	149.74	102.09
Right of use assets	4A	2.75	3.18	254.18	286.32
Intangible assets	4	-	-	-	0.38
Financial assets					
(i) Other financial assets	5	1.22	1.28	112.76	115.13
Total non-current assets		5.59	5.60	516.69	503.92
Current assets					
Inventories	6	25.52	18.93	2,358.82	1,702.56
Financial assets					
(i) Trade receivables	7	8.76	6.51	809.69	585.51
(ii) Cash and cash equivalents	8	10.52	12.50	972.36	1,124.25
(iii) Other financial assets	5	1.38	0.06	127.55	5.40
Other current assets	9	1.63	0.55	150.66	49.47
Total current assets		47.81	38.55	4,419.08	3,467.19
Total assets		53.40	44.15	4,935.77	3,971.11
Equity and Liabilities					
Equity					
Equity share capital	10	0.26	0.26	22.96	22.96
Other equity	11	21.20	20.93	1,960.59	1,883.78
Total equity		21.46	21.19	1,983.55	1,906.74
Liabilities					
Non-current liabilities					
Financial liabilities					
(i) Lease liabilities	12	1.08	1.91	99.82	172.01
Total non current liabilities		1.08	1.91	99.82	172.01
Current liabilities					
Financial liabilities					
(i) Lease liabilities	12A	1.91	1.58	176.54	141.80
(ii) Trade payables	13	8.74	6.49	807.84	583.71
Other financial liabilities	14	13.65	4.87	1,261.67	438.01
Other current liabilities	15	2.71	2.26	250.49	203.27
Provisions	16	2.75	4.75	254.19	426.74
Current tax liability (net)	17	1.10	1.10	101.67	98.83
Total current liabilities		30.86	21.05	2,852.40	1,892.36
Total equity and liabilities		53.40	44.15	4,935.77	3,971.11
Summary of material accounting policies	3				

The summary of material accounting policies and other explanatory information are an integral part of these financial statements.

This is Translated Version of Balance Sheet referred to in our report of even date

For J C Bhalla & Co.
Chartered Accountants
Firm's Registration No: 001111N

Akhil Bhalla
Partner
Membership No: 505002

Place: New Delhi
Date: 08 October 2025

For and on behalf of the Board of Directors of
Integris Medtech Limited (Holding company)

Probir Das
Executive Director and Group CEO
DIN Number: 06588579

Hemant Sultania
Chief Financial Officer

Place: New Delhi
Date: 08 October 2025

J C BHALLA & CO. Chartered Accountants

LAMED Vertriebsgesellschaft
Translated Version of Comprehensive Income for the Financial year ended 31 March 2025
(All amounts in EURO/INR lakhs, unless stated otherwise)

Particulars	Notes	EURO For the year ended 31 March 2025	EURO For the period from 01 June 2023 to 31 March 2024	INR For the year ended 31 March 2025	INR For the period from 01 June 2023 to 31 March 2024
Income					
Revenue from operations	18	109.00	79.75	9,892.98	7,161.55
Other income	19	1.07	0.21	97.12	19.08
Total Income		110.07	79.96	9,990.10	7,180.63
EXPENSES					
Purchases of stock-in-trade	20	54.19	29.79	4,917.46	2,675.14
Changes in inventories	20A	-6.59	3.14	(598.12)	281.97
Employee benefits expense	21	20.48	18.37	1,858.79	1,649.63
Finance costs	22	0.27	0.24	24.74	21.55
Depreciation and amortisation expenses	23	2.19	1.57	198.77	141.15
Other expenses	24	16.66	8.59	1,512.08	771.38
Total expenses		87.20	61.70	7,913.72	5,540.82
Profit before tax		22.87	18.26	2,076.38	1,639.81
Tax expense					
Current tax	25	-	0.90	-	80.56
Deferred tax	25	-	-	-	-
Total tax expense		-	0.90	-	80.56
Profit for the year/ period		22.87	17.36	2,076.38	1,559.25
Other comprehensive income for the year/ period				-	-
Total comprehensive income for the year/ period, after tax		22.87	17.36	2,076.38	1,559.25
Earning per equity share [nominal value of equity share Euro 1]					
Basic and diluted	26	87.95	66.77	7,986.07	5,997.13
Summary of material accounting policies	3				

The summary of material accounting policies and other explanatory information are an integral part of these financial statements.

This is the Translated Version of Statement of Profit and Loss referred to in our report of even date.

For J C Bhalla & Co.
Chartered Accountants
Firm's Registration No: 001111N

Akhil Bhalla
Partner
Membership No: 505002

Place: New Delhi
Date: 08 October 2025

For and on behalf of the Board of Directors of
Integris Medtech Limited (Holding company)

Probir Das
Executive Director and Group CEO
DIN Number: 06588579

Hemant Sultania
Chief Financial Officer

Place: New Delhi
Date: 08 October 2025

LAMED Vertriebsgesellschaft
Translated Version of Statement of Cashflows for the Financial year ended 31 March 2025
(All amounts in EURO/INR lakhs, unless stated otherwise)

Particulars	EURO For the year ended 31 March 2025	EURO For the period from 01 June 2023 to 31 March 2024	INR For the year ended 31 March 2025	INR For the period from 01 June 2023 to 31 March 2024
A. Cash flow from operating activities				
Profit before tax	22.87	18.26	2,076.38	1,639.81
Non-cash adjustments:				
Depreciation and amortisation expenses	2.19	1.57	198.77	140.99
Interest income	(0.61)	(0.04)	(55.36)	(3.59)
Finance costs	0.27	0.24	24.74	21.55
Foreign Currency Translation Reserve	-	-	-	-
Operating profit before working capital changes	**24.72**	**20.03**	**2,244.52**	**1,798.76**
Adjustments for changes in working capital:				
Movement in inventories	(6.59)	3.14	(598.12)	281.97
Movement in trade receivables	(2.25)	1.02	(204.21)	91.60
Movement in other current and financial assets	(2.34)	3.90	(212.38)	350.22
Movement in trade payables	2.25	(1.10)	204.21	(98.78)
Movement in other liabilities and provisions	4.85	(2.84)	439.74	(255.03)
Total cash generated from operations	**20.64**	**24.15**	**1,873.76**	**2,168.74**
Taxes paid	-	(2.08)	-	(186.78)
Net cash generated from operating activities [A]	**20.64**	**22.07**	**1,873.76**	**1,981.96**
B. Cash flow from investing activities				
Purchase of property, plant and equipment, Intangible and ROU	(0.95)	(0.49)	(86.22)	(44.00)
Net cash used in investing activities [B]	**(0.95)**	**(0.49)**	**(86.22)**	**(44.00)**
C. Cash flow from financing activities				
Interest paid	-	(0.01)	-	(0.90)
Repayments of long-term borrowings (refer note 29)	-	(3.00)	-	(269.40)
Dividend paid (net)	(19.91)	(10.00)	(1,807.06)	(898.00)
ESOP's contribution from parent entity	0.27	-	24.51	-
Repayment of principal portion of lease liabilities (refer note 30)	(1.79)	(1.29)	(162.46)	(115.84)
Repayment of interest portion of lease liabilities (refer note 30)	(0.24)	(0.23)	(21.78)	(20.66)
Net cash used in financing activities [C]	**(21.67)**	**(14.53)**	**(1,966.80)**	**(1,304.80)**
Net change in cash and cash equivalents [A+B+C]	**(1.98)**	**7.05**	**(179.26)**	**633.16**
Cash and cash equivalents at the beginning of the year	12.50	5.45	1,124.25	487.18
Effect of Exhange Rates on Cash			27.37	3.91
Closing cash and cash equivalents	**10.52**	**12.50**	**972.36**	**1,124.25**
Balances with banks (refer note 8)	10.52	12.50	972.36	1,124.25
Cash and bank balances	**10.52**	**12.50**	**972.36**	**1,124.25**

Notes:
1. The above cash flow statement has been prepared under the "Indirect Method" as set out in Indian Accounting Standard 7 (Ind AS-7) on "Statements of Cash Flows".

The summary of material accounting policies and other explanatory information are an integral part of these financial statements.

This is the Translated Version of Statement of Cash Flows referred to in our report of even date.

For J C Bhalla & Co.
Chartered Accountants
Firm's Registration No: 001111N

Akhil Bhalla
Partner
Membership No: 505002

Place: New Delhi
Date: 08 October 2025

For and on behalf of the Board of Directors of
Integris Medtech Limited (Holding company)

Probir Das
Executive Director and Group CEO
DIN Number: 06588579

Hemant Sultania
Chief Financial Officer

Place: New Delhi
Date: 08 October 2025

LAMED Vertriebsgesellschaft
Translated Version of Statement of Change in Equity for the Financial year ended 31 March 2025
(All amounts in EURO/INR lakhs, unless stated otherwise)

A. Equity share capital

Particulars	Notes	Number of Shares	Total
Balance as at 31 May 2023		26,000	0.26
Changes in equity share capital during the period		-	-
Balance as at 31 March 2024	10	26,000	0.26
Changes in equity share capital during the year		-	-
Balance as at 31 March 2025	10	26,000	0.26

B. Other equity

Particulars		Retained earning EURO	Deemed Equity EURO	Total EURO	Retained earning INR	Deemed Equity INR	Total INR
Balance as at 31 May 2023		18.49	-	18.49	1,652.82	-	1,652.82
Add: Profit for the period		17.36	-	17.36	1,559.25	-	1,559.25
Less: Dividend declared during the period		(14.92)	-	(14.92)	(1,339.82)	-	(1,339.82)
Exchange Gain Loss		-	-	-	11.10	-	11.10
Balance as at 31 March 2024	11	20.93	-	20.93	1,883.36	-	1,883.36
Add: Profit for the year		22.87	-	22.87	2,076.38	-	2,076.38
Less: Dividend declared during the year		(22.87)	-	(22.87)	(2,075.68)	-	(2,075.68)
Add: ESOP charge from Holding Company (Refer note 11)		-	0.27	0.27	-	24.53	24.53
Exchange Gain Loss		-	-	-	50.27	0.45	50.72
Balance as at 31 March 2025		20.93	0.27	21.20	1,934.32	24.98	1,959.30

This is the Translated Version of Statement of Changes in Equity referred to in our report of even date.

For J C Bhalla & Co.
Chartered Accountants
Firm's Registration No: 001111N

Akhil Bhalla
Partner
Membership No: 505002

Place: New Delhi
Date: 08 October 2025

For and on behalf of the Board of Directors of
Integris Medtech Limited (Holding company)

Probir Das
Executive Director and Group CEO
DIN Number: 06588579

Hemant Sultania
Chief Financial Officer

Place: New Delhi
Date: 08 October 2025

J C BHALLA & CO Chartered Accountants

LAMED Vertriebsgesellschaft
Summary of material accounting policies and other explanatory information
for the year ended 31 March 2025

1. Company overview

LAMED Vertriebsgesellschaft ('the Company') was incorporated on 2 August 1989 and is engaged in the business of medical device distribution. The company was acquired by Translumina GmbH on the 5 June 2023.

2. Basis of preparation

(i) Statement of compliance with Indian Accounting Standard (Ind AS)

These special purpose financial statements of the Company consisting of Balance Sheet as at 31 March, 2025, Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows, the Statement of Changes in Equity for the year then ended, the Statement of Changes in Equity for the year then ended, and notes to the financial statements, including material accounting policy information and other explanatory information (together referred to as 'Financial Statements').
As required under Schedule VI Part A item no.(11)(I)(A)(ii)(b) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations"), the Company has prepared the translated version of the audited standalone financial statements which is proposed to be uploaded on the website of the Company in connection with the Offer. These financial statements have been prepared by the management in accordance with Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India. These financial statements has been prepared under the historical cost convention on an accrual basis.

The functional currency of the Company is Euro. These financial statements have been translated by the Company into Indian Rupees in accordance with Ind AS 21 – The Effect of Changes in Foreign Currency Rates. The special purpose financial statements have been restated to Indian Rupees using an exchange rate of 1 Euro = ₹92.43 prevailing on the last day of the financial year for the balance sheet, and 1 Euro = ₹90.76 as the average rate for the profit and loss account.

(ii) Historical cost convention

The financial statements have been prepared on going concern basis in accordance with the accounting principles generally accepted in India. Further, the financial statements have been prepared on historical cost basis except for certain financial assets and financial liabilities which are measured at fair value.

(iii) Current versus non-current classification

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle i.e. 12 months.

3. Summary of material accounting policies

The financial statements have been prepared using the material accounting policies and measurement bases summarised as below. These policies are applied consistently for all the periods presented in the financial statements, except where the Company has applied certain accounting policies and exemptions upon transition to Ind AS. Further, the figures in the financials have been rounded off to nearest lakh with two decimals. Hence the figures appearing as " 0.00 " are the figures rounded off to nearest decimal lakhs.

a) Property, plant and equipment

Recognition and initial measurement
Property, plant and equipment are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. All other repair and maintenance costs are recognised in statement of profit and loss.

Subsequent measurement (depreciation method, useful lives and residual value)
Property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses. Depreciation on property, plant and equipment is provided on the straight-line method. The estimated useful lives mentioned below are different from the useful lives specified for certain categories of these assets, where applicable, as per Companies Act. The estimated useful lives followed in respect of these assets are based on management's assessment and technical advice, taking into account factors such as nature of assets, the estimated usage of pattern of the assets, the operating conditions, the past history of replacement, anticipated technological changes and maintenance support etc.

Asset class	Useful life (in years)
Computers	3
Furniture and fixtures	5-13
Plant and equipment	3-15
Computer software	3-5
Other intangibles	3-12
Office Equipment	5

Depreciation is calculated on pro rata basis from the date on which the asset is ready for use or till the date the asset is sold or disposed.

The residual values, useful lives and method of depreciation are reviewed at the end of each financial year.

J C BHALLA & CO Chartered Accountants

De-recognition
An item of property, plant and equipment and any significant component initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the statement of profit and loss, when the asset is de-recognised.

b) Intangible assets

Recognition and initial measurement
Intangible assets are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Subsequent measurement (amortisation method, useful lives and residual value)
Intangible assets are amortised as per useful lives, from the date when the assets are available for use. The estimated useful life (amortisation period) of the intangible assets is arrived basis the expected pattern of consumption of economic benefits and is reviewed at the end of each financial year and the amortisation period is revised to reflect the changed pattern, if any.

De-recognition
Intangible asset is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the statement of profit and loss, when the asset is derecognised.

c) Right of use assets and lease liabilities

A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

Classification of leases
The Company enters into leasing arrangements for various assets. The assessment of the lease is based on several factors, including, but not limited to, transfer of ownership of leased asset at end of lease term, lessee's option to extend/purchase etc.

i) Right of use assets

Recognition and initial measurement
At lease commencement date, the Company recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Company, an estimate of any costs to dismantle and remove the asset at the end of the lease (if any), and any lease payments made in advance of the lease commencement date (net of any incentives received).

Subsequent measurement
The Company depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Company also assesses the right-of-use asset for impairment when such indicators exist.

ii) Lease liabilities

At lease commencement date, the Company measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed payments) and variable payments based on an index or rate. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is re-measured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is re-measured, the corresponding adjustment is reflected in the right-of-use asset.

iii) Short-term leases

The Company has elected to account for short-term leases using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these are recognised as an expense in statement of profit and loss on a straight-line basis over the lease term.



d) Inventories

Inventories are valued at the lower of cost and net realisable value. Cost is determined on first in, first out basis, in respect of raw materials and stores and spares. Cost includes freight, taxes and duties and excludes duties and taxes that are recoverable subsequently from tax authorities.

In respect of traded goods, cost includes cost of purchase and other costs incurred in bringing the inventories to their present location and condition.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Provision for slow moving/non moving inventory is estimated and made by the management, wherever necessary, based on the past experience of the Company.

e) Cash and cash equivalents

Cash and cash equivalents comprise of balance at bank, cash on hand and short term deposits with an original maturity of three months or less.

f) Financial instruments

A Financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs. Subsequent measurement of financial assets and financial liabilities is described below.

Non-derivative financial assets

Subsequent measurement

Financial assets carried at amortised cost - A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and

- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method.

De-recognition of financial assets

A financial asset is de-recognised when the contractual rights to receive cash flows from the asset have expired or the Company has transferred its rights to receive cash flows from the asset.

Non-derivative financial liabilities

Subsequent measurement

Subsequent to initial recognition, all non-derivative financial liabilities are measured at amortised cost using the effective interest method.

De-recognition of financial liabilities

A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Impairment of financial assets

In accordance with Ind AS 109, the Company applies expected credit loss ('ECL') model for measurement and recognition of impairment loss for financial assets. ECL is provided for when there has been a significant increase in credit risk and then, factors historical trends and forward-looking information. An impairment loss is recognised either based on the 12 months' probability of default or lifetime probability of default.



Trade receivables
In respect of trade receivables, the Company applies the simplified approach of Ind AS 109, which requires measurement of loss allowance at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of such receivables

Other financial assets
In respect of its other financial assets, the Company assesses if the credit risk on those financial assets has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, the Company measures the loss allowance at an amount equal to 12-month expected credit losses, else at an amount equal to the lifetime expected credit losses.

g) Provisions, contingent assets and contingent liabilities

Provisions are recognized only when there is a present obligation, as a result of past events, and when a reliable estimate of the amount of obligation can be made at the reporting date. These estimates are reviewed at each reporting date and adjusted to reflect the current best estimates. Provisions are discounted to their present values, where the time value of money is material.

Contingent liability is disclosed for:

- Possible obligations which will be confirmed only by future events not wholly within the control of the Company or
- Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

Contingent assets are neither recognised nor disclosed except when realisation of income is virtually certain, related asset is disclosed.

h) Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised goods or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those services. Revenue is measured net of rebates, discounts and taxes. The Company applies the revenue recognition criteria to each component of the revenue transaction as set out below.

Revenue from sale of goods is recognized when goods are transferred for a price, all significant risk and rewards of the ownership have been transferred to the customer, no effective control is retained with respect to goods transferred to a degree usually associated with ownership, no significant uncertainty exists regarding the amount of consideration and collectability of amount is reasonably assured. The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for the goods excluding amounts collected on behalf of third parties (for example, indirect taxes).

A receivable is recognised by the Company when the control is transferred as this is the case of point in time recognition where consideration is unconditional because only the passage of time is required. When either party to a contract has performed, an entity shall present the contract in the balance sheet as a contract asset or a contract liability, depending on the relationship between the entity's performance and the payment.

Other operating revenue
Revenue from other allied activities is recognised once there is certainty regarding the amount of consideration and collectability of amount is reasonably assured.

Interest income
Interest income is recognised on time proportion basis considering the amount outstanding and rate applicable. For all financial assets measured at amortised cost, interest income is recorded using the effective interest rate (EIR) i.e. the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial assets.


i) Employee benefits

All employee benefits payable/available within twelve months of rendering the services are classified as short term employee benefits. Benefits such as salaries, wages, bonus, etc. are recognised in the statement of profit and loss in the period in which the employee renders the related service.

Share Based Payment:

Equity-settled share-based payments to employees are granted by the Ultimate Holding Company are measured by reference to the fair value of the equity instruments at the grant date.

The fair value determined at the grant date of the equity-settled share-based payments is expensed over the vesting period, based on the Company's estimate of equity instruments that will eventually vest, with a corresponding increase in equity. At the end of each reporting period, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity-settled employee benefits reserve.



j) Finance cost

Borrowing costs are recognised as expenses in the period in which they are incurred except for borrowing for acquisition of qualifying assets, which are capitalised upto the date, the asset is ready for its intended use. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use.

k) Taxation

Tax expense recognized in statement of profit and loss comprises the sum of deferred tax and current tax except to the extent it recognized in other comprehensive income or directly in equity.

Current tax comprises the tax payable on taxable income for the year and any adjustment to the tax payable or receivable in respect of previous years. Current tax is computed in accordance with relevant tax regulations. The amount of current tax payable or receivable is the best estimate of the tax amount expected to be paid or received after considering uncertainty related to income taxes, if any. Current tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity).

Current tax assets and liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

l) Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events including a bonus issue.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

m) New and amended standards

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. MCA has notified below new standards /amendments which were effective from 1 April, 2024.

a. Amendments to Ind AS 116 -Lease liability in a sale and leaseback The amendments require an entity to recognise lease

The amendments require an entity to recognise lease liability including variable lease payments which are not linked to index or a rate in a way it does not result into gain on Right of use asset it retains. The amendments had no impact on the Company.

b. Introduction of Ind AS 117 - Insurance Contracts

MCA notified Ind AS 117 "Insurance Contracts", a comprehensive standard that prescribe, recognition, measurement and disclosure requirements, to avoid diversities in practice for accounting insurance contracts and it applies to all companies i.e., to all "insurance contracts" regardless of the issuer. However, Ind AS 117 is not applicable to the entities which are insurance companies registered with IRDAI. The amendments had no impact on the Company.

J C BHALLA & CO Chartered Accountants

LAMED Vertriebsgesellschaft

Translated Version of Notes to the Financial Statement for the Financial year ended 31 March 2025

(All amounts in EURO/INR lakhs, unless stated otherwise)

4. Property, plant and equipments and Intangible assets

	EURO	EURO	EURO	EURO	EURO	EURO	INR	INR	INR	INR	INR	INR
Particulars	**Office Equipment**	**Furniture and Fixtures**	**Plant & Machinery**	**Computers**	**Vehicles**	**Intangible assets**	**Office Equipment**	**Furniture and Fixtures**	**Plant & Machinery**	**Computers**	**Vehicles**	**Intangible assets**
Gross block												
Balance as at 31 May 2023	**0.22**	**0.43**	**0.01**	**0.17**	**0.93**	**0.02**	**19.72**	**38.62**	**1.13**	**15.39**	**83.13**	**1.81**
Additions during the period	0.02	0.04	-	0.15	0.28	-	2.23	3.63	-	12.61	25.14	-
Disposals during the period	-	-	-	-	-	-	-	-	-	-	-	-
Exchange Difference	-	-	-	-	-	-	(0.78)	0.24	0.01	0.12	0.56	0.02
Balance as at 31 March 2024	**0.24**	**0.47**	**0.01**	**0.32**	**1.21**	**0.02**	**21.17**	**42.49**	**1.14**	**28.12**	**108.83**	**1.83**
Additions during the year	**0.06**	**0.20**	-	**0.04**	**0.65**	-	5.45	18.15	-	3.63	58.99	-
Disposals during the year	-	-	-	-	-	-	-	-	-	-	-	-
Exchange Difference	-	-	-	-	-	-	0.65	1.44	0.03	0.80	3.90	0.04
Balance as at 31 March 2025	0.30	0.67	0.01	0.36	1.86	0.02	27.27	62.08	1.17	32.55	171.72	1.87
Accumulated depreciation/ amortisation												
Balance as at 31 May 2023	**0.12**	**0.30**	**0.01**	**0.06**	**0.35**	**0.01**	10.43	26.62	1.07	5.71	30.92	0.96
Depreciation/ amortisation charged	0.02	0.02	-	0.07	0.16	**0.01**	**1.72**	**2.01**	-	**6.64**	**14.04**	**0.48**
Exchange Difference	-	-	-	-	-	-	0.07	0.17	0.01	(0.86)	1.11	0.39
Balance as at 31 March 2024	**0.14**	**0.32**	**0.01**	**0.13**	**0.51**	**0.02**	**12.22**	**28.80**	**1.08**	**11.49**	**46.07**	**1.83**
Depreciation/ amortisation charged	**0.04**	**0.04**	-	**0.10**	**0.29**	-	3.63	3.63	-	9.08	26.32	-
Exchange Difference	-	-	-	-	-	-	1.31	0.83	0.03	0.47	1.67	0.04
Balance as at 31 March 2025	0.18	0.36	0.01	0.23	0.80	0.02	17.16	33.26	1.11	21.02	74.06	1.87
Net block as at 31 May 2023	**0.10**	**0.13**	-	**0.11**	**0.58**	**0.01**	**9.29**	**11.99**	**0.06**	**9.68**	**52.21**	**0.86**
Net block as at 31 March 2024	**0.10**	**0.15**	-	**0.19**	**0.70**	-	**8.96**	**13.69**	**0.00**	**16.63**	**62.76**	**0.38**
Net block as at 31 March 2025	**0.12**	**0.31**	-	**0.13**	**1.06**	-	**10.12**	**28.83**	**0.00**	**11.53**	**97.66**	**0.00**

(i) The Company has not revalued its property, plant and equipments during the year.

(ii) No property, plant and equipments have been mortgaged/ pledged as security.



(This space has been intentionally left blank)

(All amounts in EURO/INR lakhs, unless stated otherwise)

4A. Right-of-use assets

	Amount - EURO	Amount - INR
Particulars	**Right-of-use asset***	**Right-of-use asset***
Gross block		
Balance as at 31 May 2023	**6.52**	**582.82**
Additions during the period	**0.91**	81.72
Disposals during the period	-	-
Exchange Difference	-	**3.71**
Balance as at 31 March 2024	**7.43**	**668.25**
Additions during the year	1.29	117.08
Disposals during the year	-	-
Exchange Difference	-	**19.74**
Balance as at 31 March 2025	**8.72**	**805.07**
Accumulated depreciation/ amortisation		
Balance as at 31 May 2023	**2.96**	**264.59**
Depreciation/ amortisation charged	1.29	115.78
Exchange Difference	-	1.56
Balance as at 31 March 2024	**4.25**	**381.93**
Depreciation/ amortisation charged	1.72	156.11
Exchange Difference	-	12.85
Balance as at 31 March 2025	**5.97**	**550.89**
Net block as at 31 March 2024	**3.18**	**286.32**
Net block as at 31 March 2025	**2.75**	**254.18**

(i) The Company has not revalued its right-of-use assets during the year.

*Note: During the previous period to conform with the requirements of Ind AS 116 for leases, the Right-of-use asset has been created as on the date of balance sheet and corresponding lease liabilities has been disclosed.

J C BHALLA & CO Chartered Accountants

(This space has been intentionally left blank)

5. Other financial assets	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
	Long term	**Long term**	**Long term**	**Long term**
(Unsecured, considered good)				
Non-current assets				
Security deposits*	0.04	0.04	3.70	3.60
Loan to Employee	1.18	1.24	109.07	111.53
*It represents deposit with for bank for guarantee given.	**1.22**	**1.28**	**112.76**	**115.13**
Current assets				
Loan to Employee	**0.06**	0.06	5.55	5.40
Other recoverable*	**1.32**	-	122.00	-
	1.38	**0.06**	**127.55**	**5.40**

Note: The Company's exposure to financial risk and fair value measurement related to these financial instruments is disclosed in Note 32.
*Other recoverable relates to amount receivable from Translumina GMBH on account of employee benefit expenses cross charged as on 31 March 2025, Euro 1.32 lakhs (31 March 2024 Euro Nil). (refer note 31)

6. Inventories	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Traded goods	25.52	18.93	2,358.82	1,702.56
	25.52	**18.93**	**2,358.82**	**1,702.56**

Note:

During the year ended 31 Mar 2025 an amount of Euro 0.79 lakhs was charged to statement of profit & loss account on account of damage and expiry which is included as a part of cost of goods consumed.

7. Trade receivables	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Trade receivables				
Unsecured, considered good	**8.76**	**6.51**	809.69	585.51
Unsecured, considered impaired	-	-	-	-
	8.76	**6.51**	**809.69**	**585.51**
Impairment allowance				
Unsecured, credit impaired	-	-	-	-
	8.76	**6.51**	**809.69**	**585.51**

Ageing as at 31 March 2025:

Trade receivables ageing schedule as at 31 March 2025: EURO

Particulars	Not Due	Less than 6 months	6 months - 1 year	1 - 2 year	2-3 year	More than 3 years	Total
Undisputed trade receivables:							
Considered good	5.39	2.76	0.61	-	-	-	**8.76**
	5.39	**2.76**	**0.61**	-	-	-	**8.76**

Trade receivables ageing schedule as at 31 March 2025: INR

Particulars	Not Due	Less than 6 months	6 months - 1 year	1 - 2 year	2-3 year	More than 3 years	Total
Undisputed trade receivables:							
Considered good	498.20	255.11	56.38	-	-	-	**809.69**
	498.20	**255.11**	**56.38**	-	-	-	**809.69**

Trade receivables ageing schedule as at 31 March 2024: EURO

Particulars	Not Due	Less than 6 months	6 months - 1 year	1 - 2 year	2-3 year	More than 3 years	Total
Undisputed trade receivables:							
Considered good	4.49	1.89	0.13	-	-	-	**6.51**
	4.49	**1.89**	**0.13**	-	-	-	**6.51**

Trade receivables ageing schedule as at 31 March 2024: INR

Particulars	Not Due	Less than 6 months	6 months - 1 year	1 - 2 year	2-3 year	More than 3 years	Total
Undisputed trade receivables:							
Considered good	403.83	169.99	11.69	-	-	-	**585.51**
	403.83	**169.99**	**11.69**	-	-	-	**585.51**

(i) The Company does not have any disputed trade receivables as at 31 March 2025 and 31 March 2024.
(ii) No trade receivables are due from directors or other officers of the Company either severally or jointly with any other person. Trade receivables are non-interest bearing.
(iii) The Company's exposure to financial risk and fair value measurement related to these financial instruments is disclosed in Note 32, 33.

8. Cash and cash equivalents	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Cash on Hand	0.01	0.01	0.92	0.90
Balance with banks				
- current accounts	10.51	12.49	971.44	1,123.35
	10.52	**12.50**	**972.36**	**1,124.25**

There are no repatriation restrictions with regard to cash and cash equivalents as at 31 March 2025 and 31 March 2024.

9. Other current assets	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
(Unsecured, considered good unless stated otherwise)				
Advances to suppliers	0.74	-	68.40	-
Prepaid expenses	0.66	0.33	61.00	29.68
Advances to Employees	0.23	0.22	21.26	19.79
	1.63	**0.55**	**150.66**	**49.47**

J C BHALLA & CO Chartered Accountants

10. Equity share capital	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Authorised share capital				
26,000 equity share of Euro 1 each (previous period Euro 1 each)	0.26	0.26	22.96	22.96
	0.26	**0.26**	**22.96**	**22.96**
Issued, subscribed and fully paid up				
26,000 equity share of Euro 1 each fully paid up (previous period Euro 1 each)	0.26	0.26	22.96	22.96
	0.26	**0.26**	**22.96**	**22.96**

Notes:

i) Reconciliation of equity shares outstanding at the beginning and at the end of the year

Particulars	**As at 31 March 2025**			**As at 31 March 2024**		
	Number of shares	**Amount (EURO)**	**Amount (INR)**	**Number of shares**	**Amount (EURO)**	**Amount (INR)**
Balance at the beginning of the period	26,000	0.26	22.96	26,000	0.26	22.96
Add: Issued during the year	-	-	-	-	-	-
Balance at the end of the year	**26,000**	**0.26**	**22.96**	**26,000**	**0.26**	**22.96**

ii) Rights, preferences and restrictions attached to equity shares
The Company has only one class of equity shares having par value of Euro 1 each fully paid up. Each holder of equity share is entitled to one vote per share. The Company declares and pays dividend in Euro. All shareholders are equally entitled to dividends.

iii) Details of shares held by Holding Company

Name of the equity shareholders	**As at 31 March 2025**		**As at 31 March 2024**	
	Number of shares	**%**	**Number of shares**	**%**
Translumina Gmbh	26,000	100	26,000	26,000

iv) Details of shareholder holding more than 5% share capital

Name of the equity shareholders	**As at 31 March 2025**		**As at 31 March 2024**	
	Number of shares	**%**	**Number of shares**	**%**
Translumina Gmbh	26,000	100	26,000	26,000

v) Bonus Issue, Buy back and issue of shares other than cash
The Company has neither issued any equity shares for consideration other than cash nor any bonus shares and shares bought back for the period of 5 years immediately preceding the balance sheet date.

vi) There has been no change in the shareholding pattern during the year ended 31 March 2025.

11. Other equity	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
a) Retained earnings*				
Balance at the beginning of the year/period	20.93	18.49	1,883.78	1,652.82
Add : Profit during the year/period	22.87	17.36	2,076.38	1,559.25
Retained earnings	43.80	35.85	3,960.16	3,212.07
Less: Dividend declared during the year/period	(22.87)	-14.92	(2,075.68)	(1,339.82)
Exchange Gain Loss			-	11.52
Balance at the end of the year/period	**20.93**	**20.93**	**1,884.48**	**1,883.78**
b) Deemed Equity**				
Balance at the beginning of the year/period	-	-	-	-
Add: ESOP charge from Holding Company	0.27	-	24.53	-
Exchange Gain Loss	-	-	51.58	
Balance at the end of the year/period	**0.27**	-	**76.11**	-
Total Other Equity	**21.20**	**20.93**	**1,960.59**	**1,883.78**

*During the period, Company has approved final dividend of Euro 2075.6812 lakhs.

**It represents the grant date fair value of options issued to employees of the Company by the Ultimate Holding Company under the Employee Stock Option Plan, recognized as a deemed equity contribution from the Ultimate Holding Company.



12. Lease liabilities - non-current	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Lease liabilities*	1.08	1.91	99.82	172.01
	1.08	**1.91**	**99.82**	**172.01**

12A. Lease liabilities - current	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Lease liabilities*	1.91	1.58	176.54	141.80
	1.91	**1.58**	**176.54**	**141.80**

*Note: During the previous period to conform with the requirements of Ind AS 116 for leases, the Right of use asset has been created as on the date of balance sheet and corresponding lease liability has been disclosed.

13. Trade payables	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Total outstanding dues of trade payables	8.74	6.49	807.84	583.71
	8.74	**6.49**	**807.84**	**583.71**
Due to related party (refer note 31)	-	0.07	-	0.07
Due to others	8.74	6.42	807.84	583.64
	8.74	**6.49**	**807.84**	**583.71**

1. All amounts are short-term. The carrying values of trade payables are considered to be a reasonable approximationof fair value.
2. Trade payables are non-interest bearing and are normally settled on 15-60 days terms.
3. The Company does not have any disputed trade payables as on 31 March 2025 and 31 March 2024.

Ageing as at 31 March 2025

Outstanding for following periods from due date of payment: EURO

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade payables:							
Total outstanding dues of micro enterprises and	-	-	-	-	-	-	-
Total outstanding dues of creditors	8.53	0.21	-	-	-	-	8.74

Ageing as at 31 March 2025

Outstanding for following periods from due date of payment: INR

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade payables:							
Total outstanding dues of creditors	788.50	19.34	-	-	-	-	807.84

Ageing as at 31 March 2024

Outstanding for following periods from due date of payment:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade payables:							
Total outstanding dues of creditors	6.08	0.41	-		-	-	6.49

Ageing as at 31 March 2024

Outstanding for following periods from due date of payment:

Particulars	Outstanding for following periods from due date of payment						
	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
Undisputed trade payables:							
Total outstanding dues of creditors	546.84	36.87	-		-	-	583.71

14. Other financial liabilities	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Other payable*	13.65	4.87	1,261.67	438.01
	13.65	**4.87**	**1,261.67**	**438.01**

*During the year, Company has approved final dividend of Euro 2075.6812 lakhs, balance payable is Euro 7.26 lakhs (PY Euro 4.87 lacs).
*Payable for cross charges from related party during the year Euro 6.38 lakhs (PY NIL).

J.C. BHALLA & CO. Chartered Accountants

15. Other current liabilities	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Statutory dues payable	1.82	1.31	166.22	117.823
Advance form Customer	0.89	0.95	82.27	85.443
	2.71	**2.26**	**250.49**	**203.266**

16. Provisions- current	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Provisions for:				
Bonus	1.13	3.52	104.44	316.23
Sales Incentive	0.91	0.75	84.12	67.38
Compensated absences	0.30	0.21	27.73	18.87
Customer scheme	0.41	0.27	37.90	24.26
	2.75	**4.75**	**254.19**	**426.74**

17. Current tax liabilities (net)	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Provision for corporate tax (net of prepaid taxes)	1.10	1.10	101.67	98.826
	1.10	**1.10**	**101.67**	**98.826**

(This space has been intentionally left blank)



18.Revenue from operations	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Sale of products (Refer note 34)	109.00	79.75	9,892.98	7,161.55
	109.00	79.75	9,892.98	7,161.55

19. Other income	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Interest income	0.61	0.04	55.37	3.59
Miscellaneous income	0.46	0.17	41.75	15.49
	1.07	0.21	97.12	19.08

20. Purchases of stock in trade	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Purchase of traded goods	54.19	29.79	4,917.46	2,675.14
	54.19	29.79	4,917.46	2,675.14

20A. Changes in inventories	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Traded goods as at end of the year/ period (A)	25.52	18.93	2316.23	1,699.91
Traded goods as at beginning of the year/ period (B)	18.93	22.07	1,699.91	1,981.88
Exchange Difference			18.20	-
Total (B-A)	(6.59)	3.14	(598.12)	281.97

21. Employee benefit expenses	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Salaries and wages	16.51	16.42	1,498.47	1,474.52
Social security expenses	2.07	1.50	187.88	134.70
Share based payment expenses*	1.4	-	127.07	-
Staff welfare expenses	0.5	0.45	45.38	40.41
	20.48	18.37	1,858.79	1,649.63

*Integris Medtech Limited (IML) the Ultimate Holding Company has granted employee stock options to employees of the Company that would be vested in graded manner. Based on group policy/arrangement IML has charged the fair value of such stock options, the Company has accepted such cross charge and recognised the same under employee cost.

22. Finance costs	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Interest on lease liability (refer note 30)	0.24	0.23	21.78	20.65
Interest on discounting of share based payment expenses	0.03		2.96	-
Interest on loan from bank	-	0.01	-	0.90
	0.27	0.24	24.74	21.55

23. Depreciation and amortization expenses	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Depreciation on property, plant and equipment (refer note 4)	0.47	0.27	42.66	24.41
Amortisation of intangible assets (refer note 4)	0	0.01	-	0.90
Depreciation on right-of-use assets (refer note 4A)	1.72	1.29	156.11	115.84
	2.19	1.57	198.77	141.15

(This space is intentionally left blank)

J C BHALLA & CO Chartered Accountants

24. Other expenses	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Rent (refer note 30)	0.42	0.43	38.12	38.61
Power & Fuel	0.06	0.04	5.45	3.59
Administrative expenses	0.25	0.22	22.69	19.76
Bank Charges	0.03	0.02	2.72	1.80
Forex exchange loss	0.04	-	3.63	-
Rates and taxes	0.08	0.04	7.26	3.59
Sales promotion expenses	2.62	1.56	237.79	140.08
Repairs and maintenance	1.48	1.50	134.33	134.70
Insurance	0.46	0.08	41.75	7.18
Travelling and conveyance expenses	2.50	1.89	226.90	169.72
Management support services *	5.23	-	474.68	-
Printing and Stationary	0.16	0.10	14.52	8.98
Outward Freight	1.49	0.81	135.24	72.74
Packaging	0.30	0.52	27.23	46.70
Legal and professional charges	1.14	1.02	103.47	91.60
Miscellaneous expenses	0.40	0.36	36.30	32.33
	16.66	**8.59**	**1,512.08**	**771.38**

*Certain central administrative and management support costs are incurred by Ultimate Holding company and fellow subsidiary on behalf of group companies. These costs are recharged to group companies based on appropriate allocation methodology i.e. revenue contribution. The policy ensures that each entity bears its fair share of group-wise expenses. All cross-charges are conducted at cost plus a margin as per transfer pricing guidelines.

25. Tax Expense	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
(a) Amounts recognised in the statement of profit and loss				
Current tax				
Current tax on profits for the period (Refer note below)	-	0.90	-	80.56
Deferred tax charge				
Deferred tax charge for the period	-	-	-	-
Income tax expense recognised in the statement of profit and loss	**-**	**0.90**	**-**	**80.56**

(b) Reconciliation of effective tax rate	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Accounting profit before income tax	22.87	18.26	**2,076.38**	**1,639.81**
Less: Distribution of dividend (Refer note below)	22.87	14.92	2,075.68	1,339.82
Profit before income tax after distribution of dividend	**(0.00)**	**3.34**	**0.70**	**300.00**
Applicable tax rate	26.79%	26.79%	26.79%	26.79%
Tax expense at statutory income tax rate	(0.00)	0.89	0.19	80.35
Others	0.00	0.01	(0.19)	0.21
Income tax expense at effective tax rate reported in the Statement of Profit and Loss	**-**	**0.90**	**-**	**80.56**

Note - Distribution of dividend is excluded from the profit before tax for the period for computing the current tax in accordance with the profit transfer agreement entered with Translumina GmbH (Ultimate Holding Company) as the same will be taxable/adjustable in the hands of Holding Company. Accordingly in the current year no tax was required to be paid in the hands of Company.

26. Earning per share

The calculation of profit attributable to equity shareholders and weighted average numbers of equity shares outstanding for purpose of basic/diluted earning per share calculation are as follows-

Net profit attributable to equity shareholders	EURO	EURO	INR	INR
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Net profit for the year	22.87	17.36	2,076.38	1,559.25
Nominal value of equity share (Euro.)	1.00	1.00	1.00	1.00
Total number of equity shares outstanding at the beginning of the year	26,000	26,000.00	26,000	26,000
Total number of equity shares outstanding at the end of the year	26,000	26,000.00	26,000	26,000
Weighted average number of equity shares	26,000	26,000.00	26,000	26,000
(1) Basic earning per equity share of Euro 1 each (in Euro.)	87.95	66.77	7,986.07	5,997.13
(2) Diluted earning per equity share of Euro 1 each (in Euro.)	87.95	66.77	7,986.07	5,997.13

J C BHALLA & CO Chartered Accountants

(This space has been intentionally left blank)

27. Capital management

For the purpose of the Company's capital management, capital includes issued equity capital, securities premium and all other equity reserves attributable to the equity shareholders. The Company includes within net debt, borrowings less cash and cash equivalents, other bank balances and current investments. The primary objective of the Company's capital management is to maximise the shareholder value. The Company is not subject to any externally imposed capital requirements.

Particulars	EURO As at 31 March 2025	EURO As at 31 March 2024	INR As at 31 March 2025	INR As at 31 March 2024
Lease liabilities	2.99	3.49	276.37	313.82
Less: Cash and cash equivalents	(10.52)	(12.50)	(972.36)	(1,124.25)
Net debt	**(7.53)**	**(9.01)**	**(696.00)**	**(810.43)**
Total capital	21.46	21.19	1,983.55	1,906.74
Capital and net debt	**13.93**	**12.18**	**1,287.55**	**1,096.31**
Gearing ratio	**(54%)**	**(74%)**	**(54%)**	**(74%)**

28. Contingent liabilities and commitments

The Company has no contingent liabilities and commitments as at 31 March 2025 and 31 March 2024

29. Reconciliation of liabilities arising from financing activities

The changes in the Company's liabilities arising from financing activities can be classified as follows:

Particulars	EURO Borrowings	EURO Lease liabilities	INR Borrowings	INR Lease liabilities
Balance as at 1 June 2023	3.00	3.87	268.14	345.90
Cash flows:				
- Repayment	(3.00)	(1.52)	(269.40)	(136.50)
Non cash:				
- Addition in leases		0.92		82.62
- Interest expense		0.23	-	20.65
Exchange Gain/Loss	-	-	1.26	1.15
Balance as at 31 March 2024	-	3.49	-	313.82
Cash flows:				
- Repayment	-	(2.03)	-	(184.25)
Non cash:				
- Addition in leases	-	1.29	-	117.08
- Interest expense	-	0.24	-	21.78
Exchange Gain/Loss	-	-	-	7.93
Balance as at 31 March 2025	-	2.99	-	276.37

30. Lease related disclosures

The Company has leases for cars and office premises. With the exception of short-term lease underlying assets, each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. Variable lease payments which do not depend on an index or a rate are excluded from the initial measurement of the lease liability and right of use assets. Each lease generally imposes a restriction that, unless there is a contractual right for the Company to sublease the asset to another party, the right-of-use asset can only be used by the Company. Some leases contain an option to extend the lease for a further term. The Company is prohibited from selling or pledging the underlying leased assets as security.

A. Set out below are the carrying amounts of lease liabilities and the movements during the period:

Particulars	EURO For the year ended 31 March 2025	EURO Period from 01 June 2023 to 31 March 2024	INR For the year ended 31 March 2025	INR Period from 01 June 2023 to 31 March 2024
Opening Balance	3.49	3.87	313.82	345.90
Additions	1.29	0.92	117.08	82.62
Deletions	-	-	-	-
Accretion of interest	0.24	0.23	21.78	20.65
Repayments	(2.03)	(1.52)	(184.25)	(136.50)
Exchange Gain/Loss	-	-	7.93	1.15
Closing balance	2.98	3.49	276.37	313.82
- Current	1.91	1.58	176.54	142.11
- Non Current	1.08	1.91	99.82	171.79

B. Lease payments not included in measurement of lease liability

The expense relating to payments not included in the measurement of the lease liability is as follows:

Particulars	For the year ended 31 March 2025	Period from 01 June 2023 to 31 March 2024	For the year ended 31 March 2025	Period from 01 June 2023 to 31 March 2024
Short-term leases	0.42	0.43	38.12	38.61
Total	**0.42**	**0.43**	**38.12**	**38.61**

C. Total cash outflow for long term leases for the year ended 31 March 2025 is Euro 2.03 lakhs (previous year Euro 1.53 lakhs).

D. Maturity of lease liabilities

The lease liabilities are secured by the related underlying assets. Future minimum lease payments were as follows:

EURO

31 March 2025	Minimum lease payments due				
Particular	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	2.07	0.90	0.23	-	3.20
Interest expense	0.16	0.05	0.01	-	0.22
Net present values	**1.91**	**0.86**	**0.22**	**-**	**2.99**

INR

31 March 2025	Minimum lease payments due				
Particular	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	187.88	81.70	20.88	-	290.45
Interest expense	14.52	4.54	0.91	-	19.97
Translation Difference	3.19	2.33	0.37	-	(34.05)
Net present values	**176.54**	**79.49**	**20.33**	**-**	**276.37**

EURO

31 March 2024	Minimum lease payments due				
Particular	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	1.89	1.58	0.41	0.02	3.90
Interest expense	0.31	0.09	0.01	-	0.41
Net present values	**1.58**	**1.49**	**0.40**	**0.02**	**3.49**

INR

31 March 2024	Minimum lease payments due				
Particular	Within 1 year	1-2 years	2-3 years	More than 3 years	Total
Lease payments	169.72	141.88	36.82	1.80	350.22
Interest expense	27.84	8.08	0.90	-	36.82
Translation Difference	0.06	0.06	0.02	0.00	0.14
Net present values	**141.95**	**133.86**	**35.94**	**1.80**	**313.54**

E. The effective rate of interest for lease liability is 7.50% p.a (31 March 2024 : 7.50%).

J C BHALLA & CO Chartered Accountants

LAMED Vertriebsgesellschaft
Translated Version of Notes to the Financial Statement for the Financial year ended 31 March 2025
(All amounts in Euro lakhs, unless stated otherwise)

31. Related party disclosure

In accordance with the requirements of Ind AS 24, 'Related Party Disclosures', the names of the related party where control exists/able to exercise significant influence along with the transactions and year-end balances with them as identified and certified by the management are given below:

a) List of related parties and relationships:

Nature of relationship	Name of related party
i) Ultimate Holding Company	Everstone Capital Partners III LLP
ii) Immediate Holding Company	Integris Medtech Limited (Formerly known as Integris Medtech Private Limited and Integris Health Private Limited)
iii) Holding Company	Translumina GmbH
iv) Fellow subsidiary	Blue Medical Devices B.V.
	Translumina Therapeutics LLP (until 24 January 2025)
	Translumina Therapeutics Private Limited (w.e.f 25 January 2025)
	Translumina Medical Devices Trading L.L.C (w.e.f 24 April 2024)
	Translumina France SAS (upto 31 July 2024)
	Transhealth Private Limited
	Transvalve health Private Limited
	Artic GmbH
iv) Key managerial personnel	
Director	Ms. Ingrid Frank

(b) The following transactions were carried out with related parties in the ordinary course of business	**EURO**	**EURO**	90.76132531 **INR**	89.80 **INR**
Particulars	**For the year ended 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**Amount in INR**	**Amount in INR**
Loan given (excluding accrued interest)				
Translumina GmbH	15.03	10.00	1,363.80	898.00
Revenue from operations				
Translumina GmbH	0.16	-	14.59	-
Interest income				
Translumina GmbH	0.58	0.04	52.88	3.59
Salary Cross Charge				
Translumina GmbH	1.84	-	166.63	-
Management support services				
Integris Medtech Limited	0.60	-	54.46	-
Translumina Therapeutics LLP	3.64		330.78	
Translumina Therapeutics Private Limited	0.98	-	89.25	-
Share based payment expenses		-		-
Integris Medtech Limited	1.40	-	127.07	-
Interest on discounting of share based payment expenses				
Integris Medtech Limited	0.03	-	2.72	-
Distribution of profits				
Translumina GmbH	22.87	14.92	2,075.71	1,339.41
Repayment of loan				
Ms. Ingrid Frank	0.06	0.05	5.64	4.49
Payment of bonus				
Ms. Ingrid Frank	3.73	3.30	338.43	296.10
Purchase of goods				
Blue Medical Devices BV	1.38	0.03	124.94	2.69
Translumina GmbH	0.78	0.02	71.01	2.05

(c) The following balances were outstanding as at with related parties in the ordinary course of business	**EURO**	**EURO**	92.43 **INR**	89.94 **INR**
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**Amount in INR**	**Amount in INR**
Other recoverable				
Translumina GMBH	1.32	-	122.01	-
Other Payables				
Translumina GMBH (Dividend payable)	7.27	4.87	671.97	438.01
Integris Medtech Limited	1.75	-	161.75	-
Translumina Therapeutics Private Limited	4.63	-	427.75	-
Deemed Equity				
ESOPs contribution from Ultimate Holding Company	0.27	-	24.96	-
Trade payables				
Blue Medical Devices B.V.	-	0.03	-	2.79
Ingrid Frank	-	0.04	-	3.15
Loan to employees				
Ingrid Frank	1.24	1.30	114.61	116.92
Provision for bonus				
Ingrid Frank	1.13	3.52	104.45	316.48

J C BHALLA & CO Chartered Accountants

32. Financial instruments risk

Financial risk management objectives and policies

The Company is exposed to various risks in relation to financial instruments. The main types of financial risks are market risk, credit risk and liquidity risk.

The management of the Company monitors and manages the financial risks relating to the operations of the Company on a continuous basis. The Company does not engage in the trading of financial assets for speculative purposes. The most significant financial risks to which the Company is exposed are described below.

I) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices. The Company is exposed to market risk through its use of financial instruments and specifically to foreign currency risk and interest rate risk which result from its operating, investing and financing activities.

i) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The functional currency of the Company is Euro. There is no exposures of foreign currency exchange rates as at 31 March 2025 and it mainly relies on natural hedge.

ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is not exposed to changes in market interest rates as Company does not have any borrowings outstanding as at 31 March 2025.

II) Credit risk

Credit risk is the risk that a counterparty fails to discharge an obligation to the Company. The Company is operating through a network of distributors and other distribution partners based at different locations. The Company is exposed to this risk for various financial instruments, for example receivables from customers. The Company's maximum exposure to credit risk is limited to the carrying amount of financial assets recognised at end of each reporting period, as summarised below:

Particulars	Note	EURO As at 31 March 2025 Amortised cost	EURO As at 31 March 2024 Amortised cost	INR As at 31 March 2025 Amortised cost	INR As at 31 March 2024 Amortised cost
Financial assets					
Trade receivables	7	8.76	6.51	809.69	585.51
Cash and cash equivalents	8	10.52	12.50	972.36	1,124.25
Other financial assets	5	2.60	0.04	240.32	120.52
Total financial assets		**21.88**	**19.05**	**2,022.37**	**1,830.28**

The Company continuously monitors receivables and defaults of customers and other counterparties, and incorporates this information into its credit risk controls.

The credit risk for cash and cash equivalents is considered negligible, since the counterparties are reputable banks.

III) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due.

As at 31 March 2025, the Company's financial liabilities have undiscounted contractual maturities as summarised below:

EURO

31 March 2025	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Trade payables	8.74	-	-	-	8.74
Lease liabilities (current and non current)	2.07	0.91	0.23	-	3.21
Other financial liabilities	13.65	-	-	-	13.65
Total	**24.46**	**0.91**	**0.23**	**-**	**25.60**

INR

31 March 2025	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Trade payables	807.84	-	-	-	807.84
Lease liabilities (current and non current)	176.54	79.49	20.33	-	276.37
Other financial liabilities	1,261.67	-	-	-	1,261.67
Total	**2,246.05**	**79.49**	**20.33**	**-**	**2,345.87**

EURO

31 March 2024	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Trade payables	6.49	-	-	-	6.49
Lease liabilities (current and non current)	1.89	1.58	0.41	0.02	3.90
Other financial liabilities	4.87	-	-	-	4.87
Total	**13.25**	**1.58**	**0.41**	**0.02**	**15.26**

INR

31 March 2024	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	Total
Trade payables	583.71	-	-	-	583.71
Lease liabilities (current and non current)	141.95	133.86	35.94	1.80	313.54
Other financial liabilities	438.01	-	-	-	438.01
Total	**1,163.67**	**133.86**	**35.94**	**1.80**	**1,335.26**

33. Fair value measurements

Financial instruments by categories

The carrying value and fair values of financial instruments by categories are as follows:

Particulars	Note	EURO As at 31 March 2025 Amortised cost	EURO As at 31 March 2024 Amortised cost	INR As at 31 March 2025 Amortised cost	INR As at 31 March 2024 Amortised cost
Financial assets*					
Trade receivables	7	8.76	6.51	809.69	585.51
Cash and cash equivalents	8	10.52	12.50	972.36	1,124.25
Other financial assets	5	2.60	0.04	240.32	120.52
Total financial assets		**21.88**	**19.05**	**2,022.37**	**1,830.28**
Financial liabilities*					
Trade payables	13	8.74	6.49	807.84	583.71
Lease liabilities (current and non current)	12 & 12A	2.99	3.49	276.37	313.82
Other financial liabilities	14	13.65	4.87	1,261.67	438.01
Total financial liabilities		**25.38**	**14.85**	**2,345.87**	**1,335.54**

*Fair value of cash and cash equivalents, trade receivables, other financial assets, trade payables and lease liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. The fair value of the financial assets and liabilities is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. There are no financial assets and liabilities which are measured at fair value through profit or loss or fair value through other comprehensive income.

J C BHALLA & CO Chartered Accountants

(This space has been intentionally left blank)

34. Revenue from contracts with customers

The Company supplies medical devices including endovascular products, patches, hemostasis and other related accessories. The revenue is recognised at a point in time.

(a) Assets related to contracts with customer	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Trade receivable	8.76	6.51	809.69	585.51

(b) Reconciliation of revenue recognised in statement of profit and loss with contract price:	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**As at 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Contract price	110.45	80.92	10,024.70	7,266.62
Less: discounts, rebates, credits etc.	1.45	1.17	131.72	105.07
Total	**109.00**	**79.75**	**9,892.98**	**7,161.55**

(c)The Company has not incurred any cost for obtaining contracts except administrative cost and the same is charged to statement of profit and loss.

(d) The following table provides information about contract liabilities from contract with customers:	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**As at 31 March 2024**	**As at 31 March 2025**	**As at 31 March 2024**
Contract Liabilities				
Advance from customers	0.89	0.95	82.27	85.44
Total	**0.89**	**0.95**	**82.27**	**85.44**

(e) Changes in the contract liabilities balances during the period are as follows	EURO	EURO	INR	INR
Particulars	**As at 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**	**As at 31 March 2025**	**For the period from 01 June 2023 to 31 March 2024**
Opening balance	0.95	1.29	85.44	115.31
Addition during the period	0.89	0.95	82.27	85.44
Revenue recognised during the period	(0.95)	(1.29)	(85.44)	(115.31)
Closing balance	**0.89**	**0.95**	**82.27**	**85.44**

(f) The Company does not have transactions of more than 10% of total revenue from operations with any single external customer.

35. Other statutory informations:

(i) The Company has not traded or invested in Crypto currency or virtual currency during the period.

(ii)The Company has not advanced or loaned or invested funds to any other person or entity, including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries); or
(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

(iii) The Company has not received any fund from any person or entity, including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall :

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries); or
(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

This is the summary of material accounting policies and other explanatory information referred to in our report of even date.

For J C Bhalla & Co.
Chartered Accountants
Firm's Registration No: 001111N

Akhil Bhalla
Partner
Membership No: 505002

For and on behalf of the Board of Directors of
Integris Medtech Limited (Holding company)

Probir Das
Executive Director and Group CEO
DIN Number: 06588579

Hemant Sultania
Chief Financial Officer

Place: New Delhi
Date: 08 October 2025

Place: New Delhi
Date: 08 October 2025

J C BHALLA & CO Chartered Accountants